Boston Scientific Corporation (BSX) AI Stock Analysis

Boston Scientific Corporation develops, manufactures, and markets medical devices across various interventional medical specialties worldwide. The company operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg provides technologies for diagnosing and treating gastrointestinal, pulmonary, urological, and pelvic conditions. Rhythm and Neuro offers solutions for heart rate and rhythm disorders, including pacemakers, implantable cardioverter defibrillators, cardiac mapping systems, ablation catheters, deep brain stimulation devices, and spinal cord stimulators. Cardiovascular provides interventional cardiology products such as drug-eluting stents and imaging catheters, along with structural heart therapies, peripheral artery and venous disease treatments, and cancer embolization and ablation systems.

Between FY2021 and FY2025, Boston Scientific expanded annual revenue from $11.89B to $20.07B, achieving a 5-year revenue CAGR of 15.2%. Net income increased from $1.04B in FY2021 to $2.89B in FY2025, while diluted EPS grew from $1.63 to $3.05. In FY2025, revenue grew 19.9%, gross margin reached 69.0%, and operating margin improved to 19.8% from 15.7% in FY2024. For the trailing twelve months ended June 30, 2026, revenue totaled $21.00B with an operating margin of 22.9% and a profit margin of 17.5%. In the quarter ended June 30, 2026, revenue increased 7.5% year-over-year and earnings expanded 15.1%.

As of June 30, 2026, Boston Scientific held $539.0M in cash and short-term investments against total debt of $12.62B, resulting in net debt of $12.09B. Total assets stood at $45.22B and shareholders' equity was $24.93B, yielding a debt-to-equity ratio of 0.51 and a current ratio of 1.24. In FY2025, operating cash flow reached $4.53B and free cash flow was $3.66B. Capital expenditures totaled $876.0M, while share issuance contributed $282.0M, and common share count increased 3.4% over five years.

At $44.39 per share, Boston Scientific carries a market capitalization of $64.33B and an enterprise value of $76.75B. The stock trades at a trailing P/E of 18.0x, a forward P/E of 13.2x, and an EV/EBITDA of 13.6x. These metrics sit below the median of its S&P 500 Healthcare peers, which reflect a trailing P/E of 28.9x, a forward P/E of 16.6x, and an EV/EBITDA of 15.7x. Over the past year, BSX shares declined 54.6%, lagging the 16.8% return of the S&P 500 index.

Wall Street coverage includes 18 Strong Buy, 7 Buy, and 6 Hold ratings, with 0 Sell or Strong Sell recommendations. The mean price target is $59.24, which is 33.5% above the closing price of $44.39. For the fiscal year ending December 31, 2026, analysts estimate revenue of $21.16B and EPS of $3.24, representing 6.0% earnings growth. For FY2027, 27 analysts project revenue of $22.19B and EPS of $3.38. The company has beaten EPS expectations in all 4 of its last 4 quarters, and its next earnings date is October 28, 2026.

This page is an AI-written research summary of Boston Scientific Corporation (BSX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: BSX income statement, BSX balance sheet, BSX key metrics, BSX analyst forecast, BSX chart. See the BSX stock overview for the latest quote and news.